Overview
- Sanofi reported double‑digit Q2 sales growth and on Thursday upgraded 2026 sales guidance to about +10% at constant exchange rates while saying it will stop development of amlitelimab and discontinue itepekimab and balinatunfib to refocus R&D spend.
- SPIE posted a strong H1 with a Q2 organic growth rebound, EBITA margin expansion to 6.2%, an active bolt‑on acquisition program and the April Fitch upgrade to investment grade plus a €600 million sustainability‑linked bond issued in May.
- Bekaert said swift actions limited the impact of higher input costs from the Middle East conflict, reported like‑for‑like volume growth of about 4% and an underlying EBIT margin of 8.3% while expecting full‑year like‑for‑like sales broadly flat.
- Lectra showed improved Q2 profitability driven by SaaS recurring revenue, reported ARR of €102.6 million and confirmed its 2026–2028 roadmap targeting steady SaaS ARR growth and higher EBITDA margins.
- Smaller groups diverged: AS Silvano logged modest H1 revenue growth but a roughly 31.5% drop in net profit, and across the cohort companies said they will keep using cost pass‑through, plant rationalizations, buybacks and M&A to preserve cash and margin which could speed consolidation in fragmented European industrial services and tech markets.